Orchestra BioMed Holdings (OBIO) Amortization of Deferred Charges (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Amortization of Deferred Charges of $64000.0 for Q1 2026, down 56.46% year-over-year from $147000.0 in Q1 2025, and up 127.23% quarter-over-quarter from -$235000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Amortization of Deferred Charges for 5 consecutive years, with $64000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 56.46% year-over-year to $64000.0; the TTM figure through Mar 2026 stood at $132000.0 (down 82.33% YoY), while the FY2025 annual figure was $215000.0, down 67.13% from the prior year.
- Amortization of Deferred Charges advanced to $64000.0 in Q1 2026 per OBIO's latest filing, from -$235000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $444000.0 in Q4 2022 and bottomed at -$361000.0 in Q4 2023.
- Historically, Amortization of Deferred Charges has averaged $95058.8 across 5 years, with a median of $149000.0 in 2024.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges jumped 212.68% — and 2025, when it plunged 257.72%.
- Orchestra BioMed Holdings' Amortization of Deferred Charges stood at $444000.0 in 2022, then plunged by 181.31% to -$361000.0 in 2023, then jumped by 141.27% to $149000.0 in 2024, then slumped by 257.72% to -$235000.0 in 2025, then soared by 127.23% to $64000.0 in 2026.
- Business Quant data shows OBIO's Amortization of Deferred Charges at $64000.0 in Q1 2026, -$235000.0 in Q4 2025, and $153000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 65,000.00 |
| Mar 31, 2026 | 64,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Sep 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 46,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 36,000.00 |
| Jun 30, 2023 | 37,000.00 |
| Mar 31, 2023 | 36,000.00 |
| Dec 31, 2022 | 36,000.00 |
| Sep 30, 2022 | 36,000.00 |
| Jun 30, 2022 | 36,000.00 |
| Mar 31, 2022 | 55,000.00 |